

01st October, 2026

To,
The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Certificate from CFO Pursuant Point no. 10 of Chapter XVII of SEBI Master Circular
no. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15th October, 2025**
Ref: Commercial Papers issued under ISIN INE685A14187

Pursuant to SEBI Circular referred above, this is to inform you that the proceeds of Commercial Papers (CPs) issued by the Company under ISIN: INE685A14187 have been fully utilized as per the purpose disclosed in the Disclosure Document and other listing conditions were adhered to as required under the aforesaid SEBI Circular for the quarter ended 30th September, 2026.

Kindly take note of the above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

**SUDHIR
MENON**

Digitally signed by
SUDHIR MENON
Date: 2026.10.01
16:39:46 +05'30'

SUDHIR MENON
EXECUTIVE DIRECTOR (FINANCE) & CFO

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126
Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059
Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – investorservices@torrentpharma.com